Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...
Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...
NHSA Outlines 2025 Work Plan and 2024 Medical Insurance Status
The National Healthcare Security Administration (NHSA) last week held a press conference, addressing questions regarding...
FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...
NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business
US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...
MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis
The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...
Tianjin Healthcare Official Gao Xue Under Investigation
Gao Xue, director of the National High-value Medical Consumables Joint Procurement Office, member of the...
US BIS Imposes Export Controls on Biotech Lab Instruments
The Department of Commerce’s Bureau of Industry and Security (BIS) of the United States last...
Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...
FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC
US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...
Luye Pharma Launches Erzofri in US Market
China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house...
Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...
Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain
Xinzeyuan Medical Technology Co., Ltd, a minimally invasive surgical supply chain platform enterprise based in...
Zai Lab’s KarXT NDA Accepted by NMPA for Schizophrenia Treatment
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that a New Drug...
Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study
Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...
Wanbangde’s Huperzine A Receives FDA Clearance for HIE Study
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced receiving clearance from the...
FDA Approves Datroway for HR+/HER2- Breast Cancer Treatment
Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody and topoisomerase inhibitor conjugate co-developed by Japan-based Daiichi...
Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd has announced receiving approval from the National Medical Products...
NHSA Seeks Expert Opinions on VBP Drug Quality and Efficacy
The National Healthcare Security Administration (NHSA) has released a letter titled “Letter on Requesting Assistance...
Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...